Delves into Type 2 Diabetes Patient Demographics, Quality of Life Impact, Information-Seeking Behaviors, HCP Engagement, and Treatment Experiences
This Type 2 Diabetes in America report provides a comprehensive look at life for those living with type 2 diabetes. Using detailed quantitative data, it gives a full picture of the type 2 diabetes patient experience - from symptoms to treatment to HCP relationships to quality of life - so you can make informed, strategic decisions, identify opportunities, and understand potential challenges.
About 38 million Americans have diabetes.
Type 2 Diabetes in America 2023: Understanding the Type 2 Diabetes Patient Experience offers an in-depth look at the type 2 diabetes patient experience. This large-scale, patient-reported data leverages vital quantitative insights essential to understanding key touchpoints in the type 2 diabetes patient journey, including condition management, HCP engagement, quality of life, treatment experience and satisfaction, and much more.
What makes this report unique?
Very simply: the focus on patients. This syndicated report is one of the few studies that is based on primary research with diagnosed patients, bringing the patient voice to the forefront.
Valuable insights. Informed decisions.
This report lifts the curtain on life with type 2 diabetes, giving stakeholders an actionable look at the behaviors, attitudes, perceptions, needs, and experiences of people living with the condition. Data can be used to inform strategic decisions, including product communications, competitive assessments, concept development, landscape analyses, patient journey overlays, and forecasting inputs.
This report also addresses important questions that stakeholders may not even know to ask while offering valuable insights into must-have patient-reported data points not available anywhere else. Add-on custom data analysis opportunities are also available for an additional cost - please see the report following purchase for more information.
The analyst reaches millions of people through its portfolio of 45+ condition-specific online health communities - including Type2Diabetes.com - to provide information, connection, and support to patients and caregivers in the U.S.
This report includes a deep-dive into:
- Type 2 diabetes patient demographics
- Age, gender, ethnicity, marital status, children, employment status, income, location, insurance, and other health conditions
- Impact of type 2 diabetes on quality of life
- Recent HbA1c levels, impact on quality of life, symptoms experienced, and what patients wish others better understood
- Information-seeking behaviors
- Information sources used, plus topics of interest
- HCP engagement
- Primary HCP seen for condition, satisfaction with HCP, and discussion about brands aware of/not used
- Type 2 diabetes treatment awareness and experiences
- Aided awareness of specific treatments, treatment experience, satisfaction with current treatments, perceived control with current treatment plan, and interest/participation in clinical trials
Key questions answered in this report:
- To what extent do people say type 2 diabetes impacts their overall quality of life?
- How many patients report a recent HbA1c under 7%?
- What do patients wish others understood about type 2 diabetes?
- What percentage of patients see a specialist for type 2 diabetes treatment?
- What treatments have the highest aided brand awareness among patients?
- How many patients feel their type 2 diabetes is well-controlled on their current treatment plan?
- What percentage of patients are likely to switch or add new treatments in the next six months?
- What medications have patients discussed with their HCP?
- What are the top online resources people with type 2 diabetes use to find information?
- What kinds of content and information do patients search for?
- What percentage of patients search for information on treatment options?
Methodology
Type 2 Diabetes in America 2023: Understanding the Type 2 Diabetes Patient Experience consists of:
- A 20-minute online quantitative survey, covering demographics, comorbidities, quality of life/impact, HCP interactions, as well as treatment awareness, experiences, and discussions
- Qualitative patient insights from open-ended responses
Additional details:
- Fielded: January 16, 2023 to April 14, 2023
- Convenience sample of 2,435 respondents diagnosed with type 2 diabetes
- Respondents are age 18+, living in the U.S., and are recruited from proprietary online health communities and recruiting partners
Table of Contents
Methodology
Respondent Demographics
Research Highlights
- Condition Status and Quality of Life
- Symptoms Experienced
- Impact on Quality of Life
- Qualitative Patient Insights
Information-Seeking Behaviors
- Resources Used to Manage Health
- Types of Content/Information Sought
Treatment Awareness and Experiences
- Primary HCP Seen for Type 2 Diabetes Care
- Aided Brand Awareness of Treatments
- Treatment Usage
- Condition Control on Current Treatment and Clinical Trial Interest
- Treatment Discussions with HCP
Appendix with All Data Charts and Distributions
Products Mentioned
Brands and treatments mentioned in this report include:
- metformin (oral pill, GLUCOPHAGE®)
- ACTOS® (pioglitazone)
- AFREZZA® (insulin human)
- AMARYL® (glimepiride)
- AVANDIA® (rosiglitazone maleate)
- DiaBeta® or Micronase® (glyburide)
- FARXIGA® (dapagliflozin)
- GLUCOTROL® or GLUCOTROL XL® (glipizide)
- GLYXAMBI® (empagliflozin/linagliptin)
- INVOKANA® (canagliflozin)
- JANUMET® (sitagliptin/metformin)
- JANUVIA® (sitagliptin)
- JARDIANCE® (empagliflozin)
- ONGLYZA® (saxagliptin)
- QTERN® (dapagliflozin and saxagliptin)
- RYBELSUS® (semaglutide)
- SEGLUROMET® (ertugliflozin and metformin hydrochloride)
- STEGLATRO® (ertugliflozin)
- STEGLUJAN® (ertugliflozin and sitagliptin)
- Tradjenta® (linagliptin)
- ADLYXIN® (lixisenatide injection)
- BYDUREON® (exenatide extended-release)
- BYETTA® (exenatide)
- MOUNJARO™ (tirzepatide injection)
- OZEMPIC® (semaglutide injection)
- TRULICITY® (dulaglutide)
- Victoza® (liraglutide)
- ADMELOG® (insulin lispro injection)
- BASAGLAR® (insulin glargine)
- FIASP® (insulin aspart injection)
- HUMALOG® (insulin lispro)
- HUMULIN® R (insulin human injection)
- LANTUS® (insulin glargine)
- LEVEMIR® (insulin detemir)
- NOVOLOG® (insulin aspart)
- RYZODEG® 70/30 (insulin degludec/insulin aspart)
- SOLIQUA® 100/33 (insulin glargine and lixisenatide injection)
- TOUJEO® or TOUJEO® MAX (insulin glargine)
- TRESIBA® (insulin degludec)
- XULTOPHY® 100/3.6 (insulin degludec and liraglutide injection)
